Idera Pharmaceuticals Inc (NASDAQ:IDRA) rose 8.75% to more than 3-year high on hopes that the company will release top line data at any time between now and the end of March, shedding new light on the Company. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares after opening at $4.15 moved to $ 4.22 on last trade day and at the end of the day closed at $3.88. Company price to sales ratio in past twelve months was calculated as 3774.33 and price to cash ratio as 4.58. Idera Pharmaceuticals Inc (NASDAQ:IDRA) showed a negative weekly performance of -40.12%.
Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares gained 17.39% to $16.54. The company on Mar. 17 announced that data highlighting the potential pharmacoeconomic benefit of Zerenex(TM) (ferric citrate coordination complex), the Company’s drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy’s (AMCP) 26th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Center in Tampa, Florida. Keryx Biopharmaceuticals (NASDAQ:KERX) shares advanced 2.06% in last trading session and ended the day on $198.80. KERX return on equity ratio is recorded as -71.80% and its return on assets is -59.80%. Keryx Biopharmaceuticals (NASDAQ:KERX) yearly performance is 145.71%.
MannKind Corporation (NASDAQ:MNKD)’s shares is trading at $5.38. The company on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. MannKind Corporation (NASDAQ:MNKD) shares moved down -3.35% in last trading session and was closed at $5.20, while trading in range of $ 4.87 – 5.44.
BMO Capital Markets restated their positive rating on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note issued to investors on Wednesday, American Banking and Market News reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -6.52%. On last trading day company shares ended up $7.60. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -4.29%. Analysts mean target price for the company is $8.56.
Leave a Reply